Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.
来源：PubMed发布日期：2026-06-10作者：Wollenberg A, Silverberg JI, Legat FJ, Tauber M, Laquer VT0 次点击